©2023 十大正规平台. 版权所有.

科学 | 2023年10月4日

Targeting the Underlying Genetic Causes of Heart Disease

十大正规平台 researchers are leveraging the company’s expertise in translating genetic discoveries into potentially transformative medicines to address the root causes of certain forms of cardiovascular disease.

十大正规平台的动力 | 2023年9月25日

罕见的学者 Program Provides 支持 to College Students Living with Genetic 条件

The program was created to support U.S. college students living with one of four rare genetic conditions who have demonstrated exceptional leadership and engagement in school and community activities.

十大正规平台 Teams Use Genetic Expertise and Computational Tools to Target More Common 条件

For geneticist Daniel Gaffney, becoming an expert in how genes influence human health was not enough. His drive to improve lives with this knowledge led him to 十大正规平台, where he found a shared commitment to translating scientific advances into medicines that solve genetic problems. Since joining the company earlier this year, Dan has helped its […]

阅读更多 阅读更多
十大正规平台的动力 | 2023年7月21日

Raising a Child with Hemophilia: 十大正规平台 Employee Jess Klass Shares Her Story

After growing up with a brother living with hemophilia A and working in roles supporting the bleeding disorder community for years, Jess Klass thought she knew everything there was to know about hemophilia.

科学 | 2023年6月29日

十大正规网赌平台 Approves 十大正规平台’s Gene Therapy for a Genetic Bleeding Disorder

We’re thrilled to share that the U.S. Food and Drug Administration has approved our gene therapy for a genetic bleeding disorder. Developing the one-time therapy and bringing it over the finish line, first in Europe and now the United States, has been a global effort. Our teams have made unprecedented scientific, medical, manufacturing and regulatory […]

十大正规平台公司 | 2023年4月17日

A Message from the Chairman and CEO

Dear Stockholder of 十大正规平台: In 2022, 十大正规平台 achieved record revenue and pivoted to GAAP profitability, making it a truly transformational year for the company and laying the foundation for long-term growth. The global launch of VOXZOGO for children with achondroplasia helped drive that revenue growth. We believe conditional European approval of our gene therapy for […]